How loss of tumor suppressor drives ER+ breast cancer to metastasize to the bone

A Baylor College of Medicine-led team has uncovered how loss of tumor suppressor neurofibromin (NF1) in estrogen receptor-positive (ER+) breast cancer cells drives the cells' preference to metastasize to bone.